Entrada Therapeutics, Inc.
TRDA
$7.46
$0.010.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -42.76M | -39.72M | -39.16M | -44.13M | -43.10M |
| Total Depreciation and Amortization | 841.00K | 805.00K | 886.00K | 1.23M | 1.03M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.70M | 4.20M | 3.73M | 4.38M | 4.09M |
| Change in Net Operating Assets | 4.76M | -6.98M | 2.35M | 10.21M | 8.49M |
| Cash from Operations | -32.46M | -41.70M | -32.20M | -28.31M | -29.49M |
| Capital Expenditure | -11.00K | -44.00K | 207.00K | 171.00K | -275.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 54.96M | 27.03M | 28.91M | 48.94M | 34.07M |
| Cash from Investing | 54.95M | 26.99M | 29.12M | 49.11M | 33.80M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 350.00K | 100.00K | 192.00K | 8.00K | 337.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 350.00K | 100.00K | 192.00K | 8.00K | 337.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 22.84M | -14.61M | -2.89M | 20.80M | 4.65M |